Regencell Bioscience Holdings Limited entered into an at-the-market sales agreement with Univest Securities, LLC to issue and sell ordinary shares, with a legal opinion confirming the accuracy of tax statements in the related prospectus supplement.
Key takeaways
The company executed an at-the-market sales agreement with Univest Securities, LLC as sales agent on March 30, 2026.
The agreement allows the company to issue and sell ordinary shares with a par value of $0.00001 per share from time to time.
Sales will be made pursuant to an effective shelf registration statement on Form F-3 and a related prospectus supplement.
Ogier (Cayman) LLP provided a legal opinion confirming the accuracy of Cayman Islands tax statements in the prospectus supplement.
The sales agreement includes limitations on the number of shares sold based on registration statement limits and board authorizations.